| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Adrenergic beta-Antagonists | 25 | 2020 | 242 | 3.940 |
Why?
|
| Asthma | 25 | 2017 | 756 | 3.770 |
Why?
|
| Receptors, Adrenergic, beta-2 | 17 | 2018 | 84 | 2.720 |
Why?
|
| Nadolol | 12 | 2020 | 28 | 2.100 |
Why?
|
| Adrenergic beta-Agonists | 13 | 2020 | 94 | 1.830 |
Why?
|
| Propanolamines | 11 | 2017 | 32 | 1.330 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 9 | 2016 | 62 | 1.320 |
Why?
|
| Receptors, Adrenergic, beta | 10 | 2020 | 62 | 0.980 |
Why?
|
| Adrenergic beta-2 Receptor Antagonists | 7 | 2020 | 13 | 0.870 |
Why?
|
| Receptors, G-Protein-Coupled | 6 | 2022 | 296 | 0.760 |
Why?
|
| Propranolol | 6 | 2020 | 128 | 0.720 |
Why?
|
| Carbazoles | 5 | 2017 | 33 | 0.720 |
Why?
|
| Eosinophils | 2 | 2017 | 120 | 0.650 |
Why?
|
| Receptors, Adrenergic | 6 | 2020 | 29 | 0.600 |
Why?
|
| Drug Discovery | 2 | 2022 | 171 | 0.590 |
Why?
|
| Epithelial Cells | 3 | 2017 | 909 | 0.550 |
Why?
|
| Signal Transduction | 15 | 2020 | 4595 | 0.540 |
Why?
|
| Phenylethanolamine N-Methyltransferase | 1 | 2016 | 2 | 0.530 |
Why?
|
| Phosphodiesterase 4 Inhibitors | 1 | 2016 | 6 | 0.530 |
Why?
|
| Anti-Asthmatic Agents | 4 | 2015 | 112 | 0.500 |
Why?
|
| Animals | 56 | 2020 | 34310 | 0.490 |
Why?
|
| Inflammation | 6 | 2017 | 1446 | 0.480 |
Why?
|
| Lung | 4 | 2017 | 1487 | 0.470 |
Why?
|
| Myocardium | 10 | 2003 | 1022 | 0.460 |
Why?
|
| Mice, Inbred BALB C | 7 | 2017 | 1001 | 0.440 |
Why?
|
| Ligands | 11 | 2014 | 538 | 0.430 |
Why?
|
| Disease Models, Animal | 7 | 2017 | 4405 | 0.420 |
Why?
|
| Exercise | 4 | 2020 | 816 | 0.410 |
Why?
|
| Mucins | 3 | 2015 | 75 | 0.400 |
Why?
|
| Albuterol | 2 | 2015 | 52 | 0.370 |
Why?
|
| Dexamethasone | 1 | 2011 | 272 | 0.330 |
Why?
|
| Ovalbumin | 5 | 2017 | 319 | 0.320 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 5 | 2015 | 158 | 0.320 |
Why?
|
| Mice | 24 | 2017 | 17744 | 0.310 |
Why?
|
| Epinephrine | 4 | 2020 | 179 | 0.310 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2011 | 292 | 0.310 |
Why?
|
| Glucocorticoids | 1 | 2011 | 384 | 0.310 |
Why?
|
| Bronchodilator Agents | 1 | 2010 | 151 | 0.290 |
Why?
|
| Mice, Transgenic | 14 | 2017 | 2414 | 0.280 |
Why?
|
| Metoprolol | 1 | 2007 | 22 | 0.280 |
Why?
|
| Myocardial Contraction | 5 | 2003 | 265 | 0.270 |
Why?
|
| Adrenergic alpha-Antagonists | 5 | 2001 | 48 | 0.270 |
Why?
|
| Alprenolol | 6 | 2015 | 10 | 0.270 |
Why?
|
| Interleukin-13 | 2 | 2017 | 97 | 0.260 |
Why?
|
| Bronchi | 2 | 2017 | 99 | 0.250 |
Why?
|
| Drug Information Services | 1 | 2005 | 7 | 0.250 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2011 | 1692 | 0.250 |
Why?
|
| Receptors, Cell Surface | 2 | 1998 | 477 | 0.250 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2005 | 31 | 0.250 |
Why?
|
| Research Design | 2 | 2015 | 693 | 0.240 |
Why?
|
| GTP-Binding Proteins | 5 | 1999 | 179 | 0.240 |
Why?
|
| Models, Biological | 3 | 2015 | 1466 | 0.230 |
Why?
|
| Adrenergic beta-1 Receptor Antagonists | 2 | 2020 | 13 | 0.230 |
Why?
|
| Phenotype | 8 | 2020 | 4269 | 0.230 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2007 | 560 | 0.230 |
Why?
|
| Respiratory Hypersensitivity | 2 | 2017 | 52 | 0.220 |
Why?
|
| Bronchial Hyperreactivity | 2 | 2016 | 38 | 0.210 |
Why?
|
| Humans | 39 | 2022 | 125439 | 0.210 |
Why?
|
| Technology, Pharmaceutical | 1 | 2002 | 20 | 0.200 |
Why?
|
| Mice, Inbred C57BL | 6 | 2017 | 4420 | 0.200 |
Why?
|
| Thinking | 1 | 2002 | 35 | 0.200 |
Why?
|
| Coronary Vessels | 3 | 2003 | 530 | 0.190 |
Why?
|
| Male | 28 | 2020 | 61628 | 0.190 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2022 | 88 | 0.190 |
Why?
|
| Adrenergic alpha-Agonists | 3 | 2001 | 23 | 0.190 |
Why?
|
| Bronchoalveolar Lavage Fluid | 4 | 2015 | 149 | 0.190 |
Why?
|
| Pharmacology, Clinical | 1 | 2001 | 5 | 0.190 |
Why?
|
| T-Lymphocytes | 2 | 2020 | 1720 | 0.190 |
Why?
|
| Protein Transport | 1 | 2022 | 369 | 0.180 |
Why?
|
| Receptors, Serotonin | 3 | 1989 | 42 | 0.170 |
Why?
|
| Databases, Factual | 1 | 2005 | 1174 | 0.170 |
Why?
|
| Muscle, Smooth | 5 | 2014 | 136 | 0.170 |
Why?
|
| Drug Therapy, Combination | 2 | 2016 | 1173 | 0.170 |
Why?
|
| Norepinephrine | 5 | 1993 | 177 | 0.170 |
Why?
|
| Cell Culture Techniques | 2 | 2020 | 276 | 0.170 |
Why?
|
| Graft vs Tumor Effect | 1 | 2020 | 6 | 0.170 |
Why?
|
| Formoterol Fumarate | 2 | 2016 | 31 | 0.160 |
Why?
|
| Methacholine Chloride | 3 | 2009 | 21 | 0.160 |
Why?
|
| Isoproterenol | 7 | 1999 | 106 | 0.160 |
Why?
|
| Viruses | 1 | 2020 | 122 | 0.160 |
Why?
|
| Drug Inverse Agonism | 2 | 2010 | 5 | 0.160 |
Why?
|
| Coronary Disease | 1 | 2003 | 675 | 0.160 |
Why?
|
| Repressor Proteins | 2 | 2014 | 826 | 0.150 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2020 | 163 | 0.150 |
Why?
|
| Ethanolamines | 3 | 2013 | 31 | 0.150 |
Why?
|
| Pharmacology | 1 | 1998 | 10 | 0.150 |
Why?
|
| Respiratory Function Tests | 2 | 2010 | 198 | 0.150 |
Why?
|
| Neuroprotective Agents | 1 | 2020 | 162 | 0.150 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2017 | 92 | 0.150 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2017 | 108 | 0.150 |
Why?
|
| Pyroglyphidae | 1 | 2017 | 9 | 0.140 |
Why?
|
| Arrestins | 2 | 2015 | 28 | 0.140 |
Why?
|
| Nuclear Proteins | 2 | 2014 | 1284 | 0.140 |
Why?
|
| Xanthines | 2 | 2013 | 14 | 0.130 |
Why?
|
| Metaplasia | 1 | 2017 | 213 | 0.130 |
Why?
|
| Mucus | 1 | 2016 | 36 | 0.130 |
Why?
|
| Monocytes | 1 | 2018 | 345 | 0.130 |
Why?
|
| Cyclopropanes | 1 | 2016 | 67 | 0.130 |
Why?
|
| Killer Cells, Natural | 1 | 2018 | 327 | 0.130 |
Why?
|
| Aminopyridines | 1 | 2016 | 56 | 0.130 |
Why?
|
| Benzamides | 1 | 2016 | 110 | 0.130 |
Why?
|
| Peptidomimetics | 1 | 2015 | 12 | 0.120 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2018 | 396 | 0.120 |
Why?
|
| Aspergillosis, Allergic Bronchopulmonary | 1 | 2015 | 19 | 0.120 |
Why?
|
| STAT6 Transcription Factor | 1 | 2015 | 35 | 0.120 |
Why?
|
| Mucin 5AC | 1 | 2015 | 24 | 0.120 |
Why?
|
| Drug Design | 2 | 2007 | 153 | 0.120 |
Why?
|
| Stress, Psychological | 1 | 2020 | 558 | 0.120 |
Why?
|
| Antiviral Agents | 1 | 2020 | 767 | 0.120 |
Why?
|
| Research Report | 1 | 2015 | 75 | 0.120 |
Why?
|
| Mice, Knockout | 4 | 2016 | 3754 | 0.120 |
Why?
|
| Bisoprolol | 3 | 2020 | 10 | 0.120 |
Why?
|
| Editorial Policies | 1 | 2015 | 53 | 0.120 |
Why?
|
| Prostatic Neoplasms | 2 | 2014 | 1549 | 0.120 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2020 | 1097 | 0.110 |
Why?
|
| Female | 16 | 2020 | 66888 | 0.110 |
Why?
|
| Phosphorylation | 2 | 2017 | 1638 | 0.110 |
Why?
|
| Receptors, Androgen | 2 | 2014 | 414 | 0.110 |
Why?
|
| Membrane Proteins | 1 | 2022 | 1538 | 0.110 |
Why?
|
| Nuclear Receptor Coactivator 3 | 2 | 2014 | 348 | 0.110 |
Why?
|
| Airway Resistance | 3 | 2014 | 36 | 0.110 |
Why?
|
| Pneumonia | 1 | 2017 | 325 | 0.110 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2014 | 214 | 0.110 |
Why?
|
| Kidney | 3 | 1989 | 1363 | 0.110 |
Why?
|
| Adenosine A1 Receptor Antagonists | 1 | 2013 | 3 | 0.110 |
Why?
|
| Muscle Contraction | 6 | 2014 | 188 | 0.100 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2020 | 832 | 0.100 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2017 | 538 | 0.100 |
Why?
|
| Memory, Long-Term | 1 | 2013 | 41 | 0.100 |
Why?
|
| Periodicals as Topic | 1 | 2015 | 197 | 0.100 |
Why?
|
| In Vitro Techniques | 8 | 1993 | 972 | 0.100 |
Why?
|
| Guinea Pigs | 6 | 1992 | 167 | 0.100 |
Why?
|
| Ileum | 6 | 1992 | 133 | 0.090 |
Why?
|
| Thiophenes | 1 | 1992 | 69 | 0.090 |
Why?
|
| Bronchoconstrictor Agents | 2 | 2009 | 11 | 0.090 |
Why?
|
| Cytokines | 2 | 2020 | 1288 | 0.090 |
Why?
|
| Leukocyte Count | 1 | 2011 | 251 | 0.090 |
Why?
|
| Respiratory Mucosa | 1 | 2011 | 91 | 0.090 |
Why?
|
| Memory Disorders | 1 | 2013 | 234 | 0.090 |
Why?
|
| Serotonin Antagonists | 2 | 1989 | 24 | 0.080 |
Why?
|
| Bronchoconstriction | 2 | 2015 | 17 | 0.080 |
Why?
|
| Mutation | 6 | 2014 | 5903 | 0.080 |
Why?
|
| Catecholamines | 2 | 2020 | 59 | 0.080 |
Why?
|
| HEK293 Cells | 3 | 2022 | 739 | 0.080 |
Why?
|
| Transcription, Genetic | 1 | 2014 | 1705 | 0.080 |
Why?
|
| Heart Failure | 5 | 2007 | 2298 | 0.080 |
Why?
|
| Myocytes, Cardiac | 3 | 2020 | 640 | 0.080 |
Why?
|
| Cardiomegaly | 2 | 2003 | 134 | 0.080 |
Why?
|
| Cell Proliferation | 3 | 2020 | 2372 | 0.080 |
Why?
|
| Adult | 6 | 2020 | 29635 | 0.080 |
Why?
|
| Gene Expression Regulation | 2 | 2013 | 2524 | 0.070 |
Why?
|
| Indoles | 1 | 1989 | 191 | 0.070 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2007 | 52 | 0.070 |
Why?
|
| Injections, Intraperitoneal | 1 | 2007 | 75 | 0.070 |
Why?
|
| Infusion Pumps | 1 | 2007 | 33 | 0.070 |
Why?
|
| Heart | 4 | 1997 | 731 | 0.070 |
Why?
|
| Bronchial Provocation Tests | 1 | 2007 | 14 | 0.070 |
Why?
|
| Rats | 6 | 2020 | 3727 | 0.070 |
Why?
|
| Sulfonamides | 1 | 1989 | 270 | 0.070 |
Why?
|
| Adenocarcinoma | 1 | 2014 | 1025 | 0.070 |
Why?
|
| Serotonin | 4 | 1995 | 217 | 0.070 |
Why?
|
| Lymphocyte Activation | 2 | 2020 | 700 | 0.070 |
Why?
|
| Electric Stimulation | 5 | 1993 | 325 | 0.070 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2007 | 461 | 0.070 |
Why?
|
| Quinoxalines | 1 | 1986 | 39 | 0.070 |
Why?
|
| Treatment Outcome | 3 | 2013 | 12303 | 0.070 |
Why?
|
| Endothelium, Vascular | 3 | 1995 | 491 | 0.060 |
Why?
|
| Alzheimer Disease | 1 | 2013 | 798 | 0.060 |
Why?
|
| Drug Administration Schedule | 1 | 2007 | 730 | 0.060 |
Why?
|
| Administration, Oral | 1 | 2007 | 682 | 0.060 |
Why?
|
| Neoplasms | 1 | 2020 | 2800 | 0.060 |
Why?
|
| Blotting, Western | 1 | 2007 | 1109 | 0.060 |
Why?
|
| Up-Regulation | 2 | 1997 | 875 | 0.060 |
Why?
|
| Antibodies | 1 | 2006 | 374 | 0.060 |
Why?
|
| beta-Adrenergic Receptor Kinases | 3 | 1999 | 26 | 0.060 |
Why?
|
| Double-Blind Method | 2 | 2018 | 1635 | 0.050 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2003 | 17 | 0.050 |
Why?
|
| Alternative Splicing | 1 | 2006 | 355 | 0.050 |
Why?
|
| Histamine Antagonists | 2 | 1997 | 19 | 0.050 |
Why?
|
| Cardiac Output, Low | 1 | 2003 | 67 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2003 | 682 | 0.050 |
Why?
|
| Ventricular Function, Left | 3 | 1997 | 514 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2007 | 1399 | 0.050 |
Why?
|
| Autoantibodies | 1 | 2006 | 432 | 0.050 |
Why?
|
| Renin-Angiotensin System | 1 | 2003 | 102 | 0.050 |
Why?
|
| Creativity | 1 | 2002 | 13 | 0.050 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2002 | 40 | 0.050 |
Why?
|
| Cyclic AMP | 2 | 2015 | 247 | 0.050 |
Why?
|
| Respiratory Mechanics | 1 | 2003 | 75 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2006 | 818 | 0.050 |
Why?
|
| Heart Rate | 3 | 2020 | 592 | 0.050 |
Why?
|
| Nanotechnology | 1 | 2022 | 46 | 0.050 |
Why?
|
| Luciferases | 1 | 2022 | 132 | 0.050 |
Why?
|
| Virus Internalization | 1 | 2022 | 55 | 0.050 |
Why?
|
| Immunoblotting | 2 | 2013 | 312 | 0.050 |
Why?
|
| Blood Pressure | 4 | 2020 | 1377 | 0.050 |
Why?
|
| Prostaglandin D2 | 1 | 2001 | 9 | 0.050 |
Why?
|
| I-kappa B Proteins | 1 | 2001 | 40 | 0.050 |
Why?
|
| Macrophages, Peritoneal | 1 | 2001 | 38 | 0.050 |
Why?
|
| Methiothepin | 2 | 1992 | 2 | 0.040 |
Why?
|
| Macrophage Activation | 1 | 2001 | 64 | 0.040 |
Why?
|
| Canada | 1 | 2021 | 286 | 0.040 |
Why?
|
| Pressoreceptors | 1 | 2000 | 9 | 0.040 |
Why?
|
| Microscopy, Fluorescence | 1 | 2022 | 330 | 0.040 |
Why?
|
| Rats, Inbred Strains | 3 | 1989 | 233 | 0.040 |
Why?
|
| Epoprostenol | 1 | 2001 | 69 | 0.040 |
Why?
|
| Thiazolidinediones | 1 | 2001 | 82 | 0.040 |
Why?
|
| Reflex | 1 | 2000 | 51 | 0.040 |
Why?
|
| Transcription Factors | 2 | 2020 | 2603 | 0.040 |
Why?
|
| Adrenergic Agents | 1 | 2020 | 12 | 0.040 |
Why?
|
| Heart Atria | 1 | 2002 | 316 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2020 | 29 | 0.040 |
Why?
|
| Bioreactors | 1 | 2020 | 38 | 0.040 |
Why?
|
| Rats, Long-Evans | 1 | 2020 | 102 | 0.040 |
Why?
|
| Electric Conductivity | 1 | 2020 | 89 | 0.040 |
Why?
|
| Hydrocortisone | 1 | 2020 | 217 | 0.040 |
Why?
|
| Lactic Acid | 1 | 2020 | 152 | 0.040 |
Why?
|
| Heart Ventricles | 2 | 2002 | 778 | 0.040 |
Why?
|
| G-Protein-Coupled Receptor Kinase 3 | 1 | 1999 | 11 | 0.040 |
Why?
|
| Species Specificity | 1 | 2020 | 551 | 0.040 |
Why?
|
| Maze Learning | 1 | 2020 | 128 | 0.040 |
Why?
|
| Receptors, Nicotinic | 1 | 2000 | 155 | 0.040 |
Why?
|
| Middle Aged | 2 | 2010 | 26827 | 0.040 |
Why?
|
| Adipogenesis | 1 | 2020 | 72 | 0.040 |
Why?
|
| Tissue Scaffolds | 1 | 2020 | 80 | 0.040 |
Why?
|
| Random Allocation | 1 | 2020 | 439 | 0.040 |
Why?
|
| Kinetics | 2 | 2020 | 1333 | 0.040 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2020 | 264 | 0.040 |
Why?
|
| Protein Conformation | 2 | 1997 | 836 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2020 | 621 | 0.040 |
Why?
|
| Hypoxia | 1 | 2020 | 248 | 0.040 |
Why?
|
| Histamine Agonists | 1 | 1997 | 2 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2018 | 134 | 0.040 |
Why?
|
| Tissue Engineering | 1 | 2020 | 173 | 0.040 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2001 | 376 | 0.040 |
Why?
|
| Receptors, Histamine H2 | 1 | 1997 | 12 | 0.040 |
Why?
|
| Peripheral Blood Stem Cells | 1 | 2017 | 2 | 0.040 |
Why?
|
| Thiazoles | 2 | 2013 | 98 | 0.040 |
Why?
|
| Receptor Aggregation | 1 | 1997 | 7 | 0.040 |
Why?
|
| CHO Cells | 1 | 1997 | 169 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2017 | 25 | 0.040 |
Why?
|
| Precipitin Tests | 1 | 1997 | 155 | 0.040 |
Why?
|
| Pharmaceutical Preparations | 1 | 1998 | 79 | 0.040 |
Why?
|
| Adenylyl Cyclases | 2 | 1995 | 83 | 0.040 |
Why?
|
| Antigens, CD34 | 1 | 2017 | 106 | 0.030 |
Why?
|
| Binding, Competitive | 1 | 1997 | 192 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2018 | 316 | 0.030 |
Why?
|
| Cricetinae | 1 | 1997 | 422 | 0.030 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2017 | 91 | 0.030 |
Why?
|
| Reserpine | 2 | 1987 | 12 | 0.030 |
Why?
|
| Peptides | 1 | 2020 | 812 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2020 | 1242 | 0.030 |
Why?
|
| Polymers | 1 | 1997 | 104 | 0.030 |
Why?
|
| Cystamine | 2 | 1986 | 4 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2007 | 6174 | 0.030 |
Why?
|
| Gene Expression | 3 | 2015 | 1554 | 0.030 |
Why?
|
| Clonidine | 2 | 1986 | 36 | 0.030 |
Why?
|
| Young Adult | 2 | 2020 | 9085 | 0.030 |
Why?
|
| Salmeterol Xinafoate | 1 | 2015 | 13 | 0.030 |
Why?
|
| beta-Arrestins | 1 | 2015 | 30 | 0.030 |
Why?
|
| Aspergillus niger | 1 | 2015 | 20 | 0.030 |
Why?
|
| Fetal Heart | 1 | 1996 | 120 | 0.030 |
Why?
|
| Pindolol | 1 | 1995 | 8 | 0.030 |
Why?
|
| Cell Membrane | 1 | 1997 | 464 | 0.030 |
Why?
|
| Fish Oils | 1 | 1995 | 85 | 0.030 |
Why?
|
| Cell Count | 1 | 2015 | 252 | 0.030 |
Why?
|
| Muscle Relaxation | 2 | 1993 | 16 | 0.030 |
Why?
|
| Peer Review, Research | 1 | 2015 | 47 | 0.030 |
Why?
|
| Receptors, Adrenergic, alpha-1 | 1 | 1994 | 18 | 0.030 |
Why?
|
| Cell Line | 1 | 2020 | 2755 | 0.030 |
Why?
|
| Muscle, Smooth, Vascular | 2 | 1993 | 231 | 0.030 |
Why?
|
| Cattle | 1 | 2015 | 567 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2015 | 314 | 0.030 |
Why?
|
| Tetrazolium Salts | 1 | 2013 | 15 | 0.030 |
Why?
|
| Allergens | 1 | 2015 | 252 | 0.030 |
Why?
|
| Molsidomine | 1 | 1993 | 1 | 0.030 |
Why?
|
| Sydnones | 1 | 1993 | 1 | 0.030 |
Why?
|
| Organ Size | 3 | 2003 | 441 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2013 | 309 | 0.030 |
Why?
|
| Lentivirus | 1 | 2013 | 82 | 0.030 |
Why?
|
| Vasoconstriction | 2 | 1993 | 98 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2013 | 199 | 0.030 |
Why?
|
| Hypertension | 1 | 2001 | 1332 | 0.020 |
Why?
|
| Adolescent | 1 | 2010 | 19447 | 0.020 |
Why?
|
| Androgens | 1 | 2014 | 279 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2020 | 1908 | 0.020 |
Why?
|
| Analgesics | 1 | 1993 | 127 | 0.020 |
Why?
|
| Sympathetic Nervous System | 2 | 1989 | 65 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2004 | 1960 | 0.020 |
Why?
|
| Benzopyrans | 1 | 1991 | 21 | 0.020 |
Why?
|
| Vasodilator Agents | 1 | 1993 | 202 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 375 | 0.020 |
Why?
|
| Piperazines | 1 | 1993 | 242 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 508 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2013 | 1019 | 0.020 |
Why?
|
| Synaptic Transmission | 1 | 1993 | 351 | 0.020 |
Why?
|
| Myosins | 3 | 1995 | 47 | 0.020 |
Why?
|
| Dihydroalprenolol | 1 | 1990 | 2 | 0.020 |
Why?
|
| United States | 1 | 2005 | 10924 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 1293 | 0.020 |
Why?
|
| Body Weight | 3 | 2003 | 989 | 0.020 |
Why?
|
| Sumatriptan | 1 | 1989 | 2 | 0.020 |
Why?
|
| Metergoline | 1 | 1989 | 1 | 0.020 |
Why?
|
| Phenoxybenzamine | 1 | 1989 | 12 | 0.020 |
Why?
|
| Allosteric Regulation | 1 | 1989 | 48 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2013 | 940 | 0.020 |
Why?
|
| Transfection | 1 | 2011 | 1076 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2013 | 879 | 0.020 |
Why?
|
| Membrane Potentials | 3 | 1995 | 307 | 0.020 |
Why?
|
| Perfusion | 1 | 1989 | 206 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2014 | 1756 | 0.020 |
Why?
|
| Dogs | 3 | 1993 | 773 | 0.020 |
Why?
|
| Brimonidine Tartrate | 1 | 1986 | 4 | 0.020 |
Why?
|
| Idazoxan | 1 | 1986 | 2 | 0.020 |
Why?
|
| Nordefrin | 1 | 1986 | 2 | 0.020 |
Why?
|
| Dioxanes | 1 | 1986 | 5 | 0.020 |
Why?
|
| Yohimbine | 1 | 1986 | 18 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 3419 | 0.020 |
Why?
|
| Drug Resistance | 1 | 1986 | 256 | 0.010 |
Why?
|
| Atrial Natriuretic Factor | 2 | 1995 | 52 | 0.010 |
Why?
|
| Fenoterol | 1 | 2003 | 1 | 0.010 |
Why?
|
| Receptors, Adrenergic, beta-1 | 1 | 2003 | 12 | 0.010 |
Why?
|
| Pertussis Toxin | 1 | 2003 | 28 | 0.010 |
Why?
|
| Heterotrimeric GTP-Binding Proteins | 1 | 2003 | 28 | 0.010 |
Why?
|
| Rats, Inbred WKY | 1 | 2003 | 54 | 0.010 |
Why?
|
| Angiotensinogen | 1 | 2003 | 21 | 0.010 |
Why?
|
| Rats, Inbred SHR | 1 | 2003 | 65 | 0.010 |
Why?
|
| Receptors, Angiotensin | 1 | 2003 | 21 | 0.010 |
Why?
|
| Angiotensin I | 1 | 2003 | 10 | 0.010 |
Why?
|
| Losartan | 1 | 2003 | 36 | 0.010 |
Why?
|
| Renin | 1 | 2003 | 93 | 0.010 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2003 | 55 | 0.010 |
Why?
|
| RNA, Messenger | 2 | 2003 | 2812 | 0.010 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2003 | 61 | 0.010 |
Why?
|
| Lung Compliance | 1 | 2003 | 19 | 0.010 |
Why?
|
| Receptor, Angiotensin, Type 2 | 1 | 2003 | 39 | 0.010 |
Why?
|
| Gene Transfer Techniques | 2 | 1995 | 358 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2003 | 426 | 0.010 |
Why?
|
| Ventricular Remodeling | 1 | 2003 | 184 | 0.010 |
Why?
|
| Angiotensin II | 1 | 2003 | 167 | 0.010 |
Why?
|
| Dinoprost | 2 | 1993 | 28 | 0.010 |
Why?
|
| Cardiotonic Agents | 1 | 2003 | 139 | 0.010 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2003 | 130 | 0.010 |
Why?
|
| Collagen | 1 | 2003 | 317 | 0.010 |
Why?
|
| Electrophysiology | 2 | 1993 | 272 | 0.010 |
Why?
|
| Thromboxane B2 | 1 | 2001 | 20 | 0.010 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2001 | 35 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2001 | 70 | 0.010 |
Why?
|
| Cyclopentanes | 1 | 2001 | 20 | 0.010 |
Why?
|
| Drug Interactions | 2 | 1993 | 255 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 2 | 1994 | 1338 | 0.010 |
Why?
|
| alpha7 Nicotinic Acetylcholine Receptor | 1 | 2000 | 58 | 0.010 |
Why?
|
| Autonomic Nervous System | 1 | 2000 | 48 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2001 | 210 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2001 | 626 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2001 | 297 | 0.010 |
Why?
|
| Hemodynamics | 1 | 2003 | 851 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2003 | 1192 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2001 | 360 | 0.010 |
Why?
|
| Nitric Oxide | 1 | 2001 | 485 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2003 | 3043 | 0.010 |
Why?
|
| Atrial Function | 1 | 1997 | 13 | 0.010 |
Why?
|
| Isometric Contraction | 1 | 1997 | 22 | 0.010 |
Why?
|
| Chimera | 1 | 1996 | 83 | 0.010 |
Why?
|
| Age Factors | 1 | 2003 | 2828 | 0.010 |
Why?
|
| Embryonic and Fetal Development | 1 | 1996 | 132 | 0.010 |
Why?
|
| Fetal Death | 1 | 1996 | 112 | 0.010 |
Why?
|
| DNA Primers | 1 | 1996 | 657 | 0.010 |
Why?
|
| Sarcolemma | 1 | 1995 | 23 | 0.010 |
Why?
|
| Ventricular Pressure | 1 | 1995 | 41 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 1996 | 448 | 0.010 |
Why?
|
| Radioligand Assay | 1 | 1994 | 26 | 0.010 |
Why?
|
| Type C Phospholipases | 1 | 1994 | 28 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1995 | 262 | 0.010 |
Why?
|
| Diglycerides | 1 | 1994 | 18 | 0.010 |
Why?
|
| Homozygote | 1 | 1996 | 548 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1994 | 319 | 0.010 |
Why?
|
| Exons | 1 | 1996 | 801 | 0.010 |
Why?
|
| Methoxyhydroxyphenylglycol | 1 | 1993 | 35 | 0.010 |
Why?
|
| Point Mutation | 1 | 1994 | 351 | 0.010 |
Why?
|
| Reference Values | 1 | 1994 | 719 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1996 | 1587 | 0.010 |
Why?
|
| Saphenous Vein | 1 | 1993 | 59 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2001 | 2061 | 0.010 |
Why?
|
| Swine | 1 | 1995 | 1178 | 0.010 |
Why?
|
| Nebivolol | 1 | 1991 | 5 | 0.010 |
Why?
|
| Genetic Therapy | 1 | 1994 | 688 | 0.010 |
Why?
|
| Vasoconstrictor Agents | 1 | 1986 | 135 | 0.000 |
Why?
|
| Heart Defects, Congenital | 1 | 1996 | 1830 | 0.000 |
Why?
|
| Pregnancy | 1 | 1996 | 7222 | 0.000 |
Why?
|